Sign up to save your podcasts
Or
Share Tisotumab Vedotin, HD Mtx In CNS Lymphoma & Class III BRAF Mutations
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Tisotumab Vedotin, HD Mtx In CNS Lymphoma & Class III BRAF Mutations
Tisotumab vedotin garners a regular FDA approval for metastatic cervical cancer with OS benefit data.
A lingering question that demands a focused RCT: What is the optimal dose of methotrexate in primary CNS lymphoma? I'm glad I'm not the only one with this question: https://doi.org/10.1177/10781552231176754
What, some BRAF mutations in colorectal cancer might respond to EGFR-mab therapy? https://doi.org/10.1200/OP.21.00160
View all episodes
By John Bossaer
4.9
179179 ratings
Tisotumab vedotin garners a regular FDA approval for metastatic cervical cancer with OS benefit data.
A lingering question that demands a focused RCT: What is the optimal dose of methotrexate in primary CNS lymphoma? I'm glad I'm not the only one with this question: https://doi.org/10.1177/10781552231176754
What, some BRAF mutations in colorectal cancer might respond to EGFR-mab therapy? https://doi.org/10.1200/OP.21.00160
More shows like OncoPharm
View all
JAMA Editors' Summary
130 Listeners
NEJM This Week
321 Listeners
JAMA Clinical Reviews
478 Listeners
The Curbsiders Internal Medicine Podcast
3,319 Listeners
Up First from NPR
56,111 Listeners
Core IM | Internal Medicine Podcast
1,084 Listeners
The ONS Podcast
196 Listeners
ASCO Guidelines
44 Listeners
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
695 Listeners
OncLive® On Air
22 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
318 Listeners
The Curious Clinicians
365 Listeners
WolverHeme Happy Hour
28 Listeners
Two Onc Docs
165 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
36 Listeners